This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Big Weight Loss for Vivus Drug: BioBuzz

So when I see Opexa release more of the same Tovaxin data Tuesday from a subset of patients in a failed phase II study and the stock surge 270%, all I can do is scratch my head, throw up my hands and mutter, "WTF?!?!"

Some Tough Questions for Hemispherx CEO

Let's hope that when Hemispherx Biopharma (HEB - Get Report) CEO William Carter takes to the podium this morning at the Rodman & Renshaw Investor Investment Conference, an investor or two in the audience hounds Carter with questions about Ampligen, the company's long-delayed chronic fatigue syndrome drug.

Ampligen is now 107 days past due. The FDA was supposed to issue its approval decision on May 25. At first, Carter claimed FDA telephoned the company requesting "one or two more weeks" to review Ampligen. That was months ago. More recently, Carter suggested that an FDA decision would come "in the fall."

All the while, Carter blames the FDA for the delay, citing its overworked staff and insisting that regulators have not asked the company for any additional data or information about Ampligen.

Does anyone seriously believe that now?

Carter is venturing outside his well-protected cocoon Wednesday to make a rare public appearance at an investor conference. He may have to answer actual questions that aren't pre-screened or otherwise posed by Hemispherx's sycophantic boosters.

It should be interesting.

Antigenics Vaccine Booster Buzz Unwarranted

An FDA advisory panel meets today to review Cervarix, a GlaxoSmithKline (GSK) vaccine that protects women and teenage girls from virus that causes cervical cancer.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
OREX $0.47 1.50%
OPXA $2.42 -4.00%
VVUS $1.56 -0.95%
AGEN $3.59 -2.70%
ARNA $1.70 -0.58%


Chart of I:DJI
DOW 17,757.07 -134.09 -0.75%
S&P 500 2,065.78 -15.65 -0.75%
NASDAQ 4,780.6210 -36.9730 -0.77%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs